MACUS T KUO to Argininosuccinate Synthase
This is a "connection" page, showing publications MACUS T KUO has written about Argininosuccinate Synthase.
Connection Strength
3.065
-
Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1a Degradation at the ASS1 promoter for ASS1 Derepression. Sci Rep. 2017 09 07; 7(1):10814.
Score: 0.606
-
Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1a, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation. Oncotarget. 2016 Dec 13; 7(50):82658-82670.
Score: 0.576
-
Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy. Cancer Lett. 2017 03 01; 388:54-63.
Score: 0.575
-
Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Cancer Res. 2012 May 15; 72(10):2622-33.
Score: 0.416
-
Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Mol Cancer Ther. 2009 Dec; 8(12):3223-33.
Score: 0.354
-
Arginine deprivation in cancer therapy. Curr Opin Clin Nutr Metab Care. 2015 Jan; 18(1):78-82.
Score: 0.126
-
Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Mol Cancer Ther. 2013 Nov; 12(11):2581-90.
Score: 0.115
-
Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer. 2012 Apr 24; 106(9):1481-5.
Score: 0.104
-
Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget. 2010 Aug; 1(4):246-51.
Score: 0.093
-
Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin. Oncotarget. 2015 Mar 20; 6(8):6295-309.
Score: 0.032
-
The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells. Mol Cancer Ther. 2012 Mar; 11(3):604-15.
Score: 0.026
-
Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. Curr Mol Med. 2010 Jun; 10(4):405-12.
Score: 0.023
-
Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des. 2008; 14(11):1049-57.
Score: 0.019